| P50 | author | Luu Pham | Q59545325 |
| | Barry S. Taylor | Q88249464 |
| | Eric Collisson | Q90503917 |
| | Trever G Bivona | Q90929253 |
| | Charles Rudin | Q42609280 |
| P2093 | author name string | Jenny Jiacheng Yan | |
| | David B Solit | |
| | Gideon Bollag | |
| | Sourav Bandyopadhyay | |
| | Elton Chan | |
| | Luping Lin | |
| | Saurabh Asthana | |
| | Victor Olivas | |
| | Maria M Martins | |
| | Mingxue Michelle Wang | |
| P2860 | cites work | A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib | Q54501104 |
| | BRAF and RAS mutations in human lung cancer and melanoma | Q78598197 |
| | The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner | Q21629049 |
| | Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas | Q24303940 |
| | Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 |
| | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 |
| | Cell signaling by receptor tyrosine kinases | Q24598357 |
| | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks | Q24633890 |
| | TopHat: discovering splice junctions with RNA-Seq | Q24655505 |
| | Rewired ERK-JNK signaling pathways in melanoma | Q24683737 |
| | MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 |
| | Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 |
| | Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers | Q27851710 |
| | Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. | Q27851711 |
| | Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer | Q27852128 |
| | Mutations of the BRAF gene in human cancer | Q27860760 |
| | edgeR: a Bioconductor package for differential expression analysis of digital gene expression data | Q27860819 |
| | Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing | Q28275103 |
| | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 |
| | RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 |
| | Circumventing Cancer Drug Resistance in the Era of Personalized Medicine | Q34274940 |
| | AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity | Q34511038 |
| | The cancer biomarker problem | Q34767213 |
| | Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations | Q35023498 |
| | Analysis of the transcriptional program induced by Raf in epithelial cells | Q35078119 |
| | EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib | Q35841043 |
| | The transcriptional response to Raf activation is almost completely dependent on Mitogen-activated Protein Kinase Kinase activity and shows a major autocrine component | Q35919391 |
| | Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer | Q36128435 |
| | Converting Cancer Therapies into Cures: Lessons from Infectious Diseases | Q36301709 |
| | New insight into BRAF mutations in cancer | Q36701579 |
| | Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. | Q36836677 |
| | FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. | Q39571776 |
| | Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1. | Q40022010 |
| | Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations | Q51428264 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | E748-57 | |
| P577 | publication date | 2014-02-03 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer | |
| P478 | volume | 111 | |